Given its central role in disease progression, targeting the NF-κB pathway may represent a promising therapeutic strategy for mitigating inflammation and fibrosis in NASH, underscoring the need for further mechanistic investigations [43,44]. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.